Brain sEH was recentlyvalidated as a novel target of interest for AD treatment.22−25 sEH inhibitors have shown beneficial effects in two different mousemodels of AD, SAMP8 and 5×FAD mice, in which they rescued cognitiveimpairment and reduced neuroinflammation, and other key pathologicalhallmarks (tau hyperphosphorylation and amyloid burden).22 This evidence concerns the gene EPHX2 and Alzheimer disease.